



## PERSONAL INFORMATION

**Matteo Landriscina**

 Department of Medical and Surgical Science  
 University of Foggia  
 Via Napoli 121, 71122 Foggia

 39 0881 736426

 [matteo.landriscina@unifg.it](mailto:matteo.landriscina@unifg.it)

 <https://www.unifg.it/it/rubrica/matteo-landriscina> Scopus Author's ID 6603715531

Nationality Italian

**Current Position:** Full Professor of Medical Oncology (MED/06)

**Scientific Profile:** Prof. Landriscina is a senior researcher with has a long-lasting experience in translational studies in Medical and Molecular Oncology. He spent three years in the laboratory of Dr. Thomas Maciag at the Maine Medical Center Research Institute, USA to study the molecular mechanisms of FGF1 and IL1 $\alpha$  secretion, two growth factors involved in angiogenesis, immune response and inflammation with evaluation of their role in cancer, as potential therapeutic targets. His present research topic is the study of the molecular mechanisms responsible for drug resistance in gastrointestinal malignancies with the aim to identify novel therapeutic strategies to improve the efficacy of treatments and characterize novel molecular targets. He is involved in studying the role of TRAP1/HSP90 pathway in inducing resistance to apoptosis and anticancer agents. Prof. Landriscina received research grants from the Italian Association of Cancer Research (AIRC), Lega Italiana per la Lotta ai Tumori (LILT Foundation), Italian Ministry of Education and University (PRIN), Berlucci Foundation and Regione Puglia. He is Director of the Medical Oncology and Biomolecular Therapy Unit at the Policlinico Riuniti University Hospital, being directly involved in clinical management of oncology patients, with specific focus on gastrointestinal and genitourinary cancers.

**Bibliometric Indicators:**

# Publications: 148; # Citations 4986; H index 40

## GOLDEN PARAGRAPH

## WORK EXPERIENCE

**2020, July – current**

Full Professor of Medical Oncology  
 Department of Medical and Surgical Sciences, University of Foggia, Italy  
 Main duties/responsibilities: Lecturer, Principal Investigator  
 Sector: Academic sector

**2019, January - current**

Director of the Unit of Medical Oncology and Biomolecular Therapy  
 University Hospital "Policlinico Riuniti", Foggia, Italy  
 Main duties/responsibilities: Unit Director  
 Sector: Health sector

**2011, February – 2021**

Translational Research Laboratory – Unit of Solid Tumors  
 IRCCS-CROB of Rionero in Vulture, Italy  
 Main duties/responsibilities: Principal Investigator  
 Sector: Research

**2016, July – 2020, June**

Associate Professor of Medical Oncology

Department of Medical and Surgical Sciences, University of Foggia, Italy  
Main duties/responsibilities: Lecturer, Principal Investigator  
Sector: Academic sector

#### **2004, January – 2016, June**

Assistant Professor of Medical Oncology  
Department of Medical and Surgical Sciences, University of Foggia, Italy  
Main duties/responsibilities: Lecturer, Principal Investigator  
Sector: Academic sector

#### **2004, January – 2018, December**

Medical Oncologist at the Unit of Medical Oncology  
University Hospital "Policlinico Riuniti", Foggia, Italy  
Main duties/responsibilities: Medical Oncologist  
Sector: Health sector

#### **2002, November – 2004, January**

Medical Oncologist at the Unit of Medical Oncology  
Catholic University, University Hospital "Policlinico Gemelli", Rome, Italy  
Main duties/responsibilities: Medical Oncologist  
Sector: Health sector

## EDUCATION AND TRAINING

### **1999-2002**

PhD in Oncology  
Catholic University, Rome, Italy  
Thesis title: "Molecular mechanisms of angiogenesis"

### **1998-2001**

Postdoctoral Fellowship  
Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine, USA  
Main topic: Molecular mechanisms of angiogenesis.

### **1993-1997**

Residency in Oncology  
Catholic University, University Hospital "Policlinico Gemelli", Rome, Italy  
Main topic: Tumor angiogenesis

### **1987-1993**

Degree in Medicine and Surgery  
Catholic University, University Hospital "Policlinico Gemelli", Rome, Italy

## PERSONAL SKILLS

Organisational / managerial skills

Currently responsible for a team of 15 people among researchers, medical oncologists, thesis students, PhD students (University of Foggia) and resident in medical oncology.

## ADDITIONAL INFORMATION

**Most 10 relevant publications in the last 10 Years**

1. Amoroso MR, Matassa DS, Laudiero G, Egorova AV, Polishchuk RS, Maddalena F, Piscazzi A, Paladino S, Sarnataro D, Garbi C, \*Landriscina M, Esposito F (\*co-corresponding author). TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. **Cell Death and Differentiation** 2012; 19(4):592-604.Q1
2. Piscazzi A, Costantino E, Maddalena F, Natalicchio I, Gerardi AMT, Antonetti R, Cignarelli M, Landriscina M. Activation of the RAS/RAF/ERK signaling pathway

- contributes to resistance to sunitinib in thyroid carcinoma cell lines. **Journal of Clinical Endocrinology and Metabolism**, 2012; 97(6):E898-906. Q1
3. Sciacovelli M, Guzzo G, Morello V, Frezza C, Zheng L, Nannini N, Calabrese F, Laudiero G, Esposito F, **Landriscina M**, Defilippi P, Bernardi P, Rasola A. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. **Cell Metabolism** 2013; 17(6):988-99. Q1
  4. Condelli V, Piscazzi A, Sisinni L, Matassa DS, Maddalena F, Lettini G, Simeon V, Palladino G, Amoroso MR, Trino S, Esposito F, **Landriscina M**. TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors. **Cancer Research** 2014; 74(22):6693-704. Q1
  5. Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C, Faicchia D, Maddalena F, Simeon V, Agliarulo I, Zanini E, Mazzoccoli C, Recchi C, Stronach E, Marone G, Gabra H, Matarese G, **Landriscina M\***, Esposito E (\*co-corresponding author). Oxidative metabolism drives metainflammation-induced platinum resistance in ovarian cancer. **Cell Death and Differentiation** 2016;23(9):1542-54. Q1
  6. Lettini G, Sisinni L, Condelli V, Matassa DS, Simeon V, Maddalena F, Gemei M, Lopes E, Vita G, Del Vecchio L, Esposito F, **Landriscina M**. TRAP1 regulates stemness through Wnt/ $\beta$ -Catenin pathway in human colorectal carcinoma. **Cell Death and Differentiation**, 2016;23(11):1792-1803. Q1
  7. Sisinni L, Maddalena F, Condelli V, Pannone G, Simeon V, Lopes V, Li Bergolis V, Piscazzi A, Matassa DS, Mazzoccoli C, Nozza F, Lettini G, Amoroso MR, Bufo P, Esposito F, **Landriscina M**. TRAP1 controls cell cycle progression through the regulation of CDK1 and MAD2 expression/ubiquitination in human breast, colon and lung carcinomas. **Journal of Pathology** 2017, 243(1):123-134. Q1
  8. Notarangelo T, Sisinni L, Trino S, Calice G, Simeon, **Landriscina M**. IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells. **Cancer Letters**, 2018; 433:147-155. Q1
  9. Maddalena F, Condelli V, Matassa DS, Pacelli C, Scrima R, Lettini G, Li Bergolis V, Pietrafesa M, Crispo F, Piscazzi A, Storto G, Capitanio N, Esposito F, **Landriscina M**. TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas. **Molecular Oncology** 2020;14(12):3030-3047. Q1
  10. Condelli V, Calice G, Cassano A, Basso M, Rodriquenz MG, Zupa A, Maddalena F, Crispo F, Pietrafesa M, Aieta M, Sgambato A, Tortora G, Zoppoli P, **Landriscina M**. Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas. **Cancers** 2021,13,158. Q1

## Projects/Grants

### 2021-2022

Lega Italiana per la Lotta ai Tumori (LILT)

Targeting metabolic dysregulation to bypass immune escape in human colorectal carcinoma – P.I.

100.000 EUROS

### 2016-2018

Italian Association of Cancer Research (AIRC) - IG16738

Cancer type-specific regulation of cell metabolism by TRAP1: impact on malignant phenotypes and drug resistance/design – P.I.

330.000 EUROS

### 2012-2015

Italian Ministry of Health. Young Researchers 2010 Grant - GR-2010-2310057

The role of TRAP1 in the resistance to anti-EGFR1 agents in human colorectal carcinoma – Co-P.I.

220.000 EUROS

### **2013-2015**

Italian Association of Cancer Research (AIRC) - IG13128

TRAP1 controls stress-adaptive responses of cancer cells: a novel molecular target in drug resistance – P.I.

330.000 EUROS

### **2010-2012**

Italian Association of Cancer Research (AIRC) – IG8780

Role of TRAP1, a novel antiapoptotic gene, in the resistance to anticancer therapy in colon and breast tumors – P.I.

195.000 EUROS

### **2010-2011**

Italian Ministry of Education and University – PRIN 20105EH5NS\_003

The role of TRAP1 in favoring the resistance to anticancer agents in human breast and colorectal tumors – Co-P.I.

120.000 EUROS

### **2009-2010**

Fondazione Guido Berlucchi

Role of the mitochondrial chaperone TRAP1 in the resistance to anticancer agents which inhibit the signaling of EGFR superfamily receptor” – P.I.

110.000 EUROS

### **2009-2011**

Lega Italiana per la Lotta ai Tumori (LILT)

Novel biomarkers for the early diagnosis of non-medullary familial thyroid carcinomas – Co-P.I.

65.000 EUROS

### **2004-2005**

Italian Ministry of Education and University – PRIN 2004054004\_002

Redox-dependent mechanisms involved in the regulation of human thyroid and brain tumors – Co-P.I.

35.300 EUROS

## **Conferences**

### **Most relevant Oral Communications**

- 31<sup>th</sup> Annual Meeting of the European Thyroid Association, Naples, Italy, 2006
- XXVII Italian Endocrinology Meeting Pisa, June 2008 (Plenary Session)
- National Meeting of the University Medical Oncology College (COMU), Naples. September 2012.
- 6<sup>o</sup> Meeting of Italian Thyroid Association, Foggia, December 2012
- European Cancer Congress 2014 (ESMO 2014), September 2014, Madrid.
- EACR-AACR-SIC Special Conference on “Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic”, Florence, June 2015
- ASCO 2015 Gastrointestinal Cancer Symposium, San Francisco, January 2015.
- ESMO 19<sup>th</sup> World Congress on Gastrointestinal Cancer, Barcelona, July 2017
- ESMO 2017 Congress, Madrid, Spain, September 2017

## **Honours and awards**

- Prize “T. Terranova” for the best MD thesis on Oncological, Catholic University, Italy, 1994.
- Prize for the best oral presentation to the XXIII Italian Meeting on Thyroid Diseases, Turin, Italy, 2005

***According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV***

*Foggia, 09/09/2024*

*F.to Prof. Matteo Landriscina*